Welcome to ProbeChem!Global Supplier of Chemical Probes, Inhibitors & Agonists.
Chemical Structure : IkT-148009
CAS No.: 2031185-00-7
Catalog No.: PC-20144Not For Human Use, Lab Use Only.
IkT-148009 (Risvodetinib, IkT09) is a potent, selective, orally bioavailable and brain-penetrant c-Abl inhibitor with IC50 of 33 and 14 nM for c-Abl (Abl1) and its closely related isoform c-Abl2 (Arg), respectively.
| Packing | Price | Stock | Quantity |
|---|---|---|---|
| 1 mg | $128 | In stock | |
| 5 mg | $298 | In stock | |
| 10 mg | $488 | In stock | |
| 50 mg | Get quote | ||
| 100 mg | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
IkT-148009 (Risvodetinib, IkT09) is a potent, selective, orally bioavailable and brain-penetrant c-Abl inhibitor with IC50 of 33 and 14 nM for c-Abl (Abl1) and its closely related isoform c-Abl2 (Arg), respectively.
IkT-148009 shows little to know inhibition against the other members of the c-Abl family, c-Kit, PDGFRα, and PDGFRβ with IC50 of 2975, 1009 and 881 nM, respectively.
IkT-148009 (100 mg/kg per day) suppressed c-Abl activation in the mouse brains of MPTP-treated mice.
IkT-148009 showed protection from degeneration of nigrostriatal DA neurons in mouse brain in MPTP neurotoxicity mouse model of parkinson's disease (PD), significantly reduced the MPTP-induced loss of dopamine and the loss of the DA metabolites, 3-4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), and 3-methoxytyramine (3MT).
IkT-148009 (100 mg/kg per day, 1% HPMC (hydroxypropyl methylcellulose), 1% Tween 80, and 10% PEG 400 in sterile water, oral gavage) rescued DA neuron loss, reduced pathological α-synuclein inmouse model of inherited and sporadic PD.
| M.Wt | 574.69 | |
| Formula | C33H34N8O2 | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
| Chemical Name/SMILES |
N-[4-Methyl-3-[[4-[5-(4-methyl-5-isoxazolyl)-3-pyridinyl]-2-pyrimidinyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]benzamide |
|
1. Patent US9828370B2.
2. Karuppagounder SS, et al. Sci Transl Med. 2023 Jan 18;15(679):eabp9352.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright
